Sells branded medicines and generic drugs, including complex drugs, to pharmacies, wholesalers and healthcare institutions.
Customers buy Viatris medicines, and a sale counts when the products pass to them. It also receives license payments and sales-based royalties when licensees sell products or use licensed technology.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$14.3B
10-K for FY2025, filed Feb 26, 2026
$14.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Brands
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
64%
FY2022: 61%
|
Brands, FY2025
$9.2B Sources
|
Sold outright |
|
Generics
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
36%
FY2022: 39%
|
Generics, FY2025
$5.1B Sources
|
Sold outright |
Viatris sells to wholesalers and distributors; pharmacies, pharmacy chains and care institutions may buy through wholesalers at separately arranged prices. Governments, insurers and other payers are also customers.
10-K for FY2025, filed Feb 26, 2026
Not on paper. It lost $3.5B in FY2025, but brought in more cash than it spent: $1.9B of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
Delivers Total Revenues of $3.8 Billion, Representing 5% Reported Growth Compared to Second Quarter 2025 and a U.S. GAAP Net Loss of $119…View ↗
8-K, filed May 4, 2026
On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief…View ↗
Shrinking. Revenue fell 20% in 4 years, from $17.9B in FY2021 to $14.3B in FY2025, about 5% a year.
Portfolio divestitures
Viatris has moved OTC, India API and women's healthcare businesses out of its portfolio: the older report listed planned divestitures, while the latest report describes completed divestitures.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 26, 2026OTC; API (while retaining some selective development API capabilities); Women’s health care, primarily related to our oral and injectable…View ↗
Viatris has executed various strategic initiatives, transactions and business arrangements over the last few years to return its base…View ↗
Loading...